Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Klein, Christian; Waldhauer, Inja; Nicolini, Valeria; Freimoser–Grundschober, Anne; K. Nayak, Tapan; J. Vugts, Daniëlle; Dunn, Claire; Bolijn, Marije; Benz, Jörg; Stihle, M.; M. Lang, Sabine; Roemmele, Michaele; Höfer, Thomas; van Puijenbroek, Erwin; Wittig, David; Moser, Samuel; Ast, Oliver; Brünker, Peter; H. Gorr, Ingo; Neumann, Sebastian; Cristina De Vera Mudry, Maria; Hinton, Heather; Crameri, Flavio; Saro, Jose; Evers, Stefan; Gerdes, Christian; Bacac, Marina; A.M.S. van Dongen, Guus; Moessner, Ekkehard; Umaña, Pablo

doi:10.1080/2162402x.2016.1277306

Public

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Published in OncoImmunology • Jan 11, 2017

Authors:

Christian Klein

Inja Waldhauer

Valeria Nicolini

Abstract

We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-...

Subject

Carcinoembryonic antigen

Antibody-dependent cell-mediated cytotoxicity

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!